throbber
Robert M. Williams,
`Ph.D.
`26 August 2016
`HarryA.Mar,DICFRNo.7708
`
`Exh. No.:
`1 8
`
`Guidance for Industry
`
`ANDAs: Pharmaceutical
`Solid Polymorphism
`Chemistry, Manufacturing, and Controls Information
`
`U.S. Department of Health and Human Services
`Food and Drug Administration
`Center for Drug Evaluation and Research (CDER)
`July 2007
`OGD
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 1
`
`

`
`Guidance for Industry
`ANDAs: Pharmaceutical
`Solid Polymorphism
`
`Chemistry, Manufacturing, and Controls Information
`
`Additional copies are available from:
`Office of Training and Communication
`Division of Drug Information, HFD-240
`Center for Drug Evaluation and Research
`Food and Drug Administration
`5600 Fishers Lane
`Rockville, MD 20857
`(Tel) 301-827-4573
`http://www.fda.gov/cder/guidance/index
`
`htm
`
`U.S. Department of Health and Human Services
`Food and Drug Administration
`Center for Drug Evaluation and Research (CDER)
`July 2007
`OGD
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 2
`
`

`
`INTRODUCTI ON ..............................................................................................................................................
`I.
`II. DEFINITION OF TERMS: POLYMORPHICFORMS AND POLYMORPHISM...................................2
`GENERAL PRINCIPLES OF PHARMACEUTICALSOLID POLYMORPHISM..............................2
`IH.
`A.
`IMPORTANCE OF PHARMACEUTICALSOLID POLYMORPHISM .........................
`CHARACTERIZATION OF POLYMORPHS................................. ..........................
`B.
`INFLUENCEOF POLYMORPHISM ON DRUG SUBSTANCE AND DRUG PRODUCT.................................................3
`C.
`Influence on Solubility, Dissolution, and Bioavailability (BA) and Bioequivalence (BE)..........................3
`Influence on Manufacturing of the Drug Product
`Influence on Stability......................
`POLYMORPH I SM A ND SA ME NESS I N AND A s
`
`TABLE OF CONTENTS
`
`..........................2
`
`...........................2
`
`1
`
`5
`
`1.
`
`2.
`
`3.
`
`IV.
`
`...................
`
`..
`
`.......
`
`..................4
`
`....
`
`.
`
`...................5
`
`....................................................................................
`
`V. CONSIDERATIONSFOR POLYMORPHISMIN ANDAs..........................................................................6
`A.
`INVESTIGATINGTHE IMPORTANCE OF SETTING SPECIFICATIONS FOR POLYMORPHs ........................................6
`SETTING SPECIFICATIONS FOR POLYMORPHS IN DRUG SUBSTANCES ...............................................................6
`B.
`INVESTIGATINGTHE IMPORTANCE OF SETTING SPECIFICATIONS FORPOLYMORPHS IN DRUG PRODUCTS........7
`C.
`A TTA CHMENT 1
`- DEC I S I ONTREE 1.................................................................................................................
`A TTA CHMENT 2 - DEC I S IONTREE 2 .................................................................................................................
`
`8
`
`9
`
`A TTACHMENT 3 - DEC I S IONTRE E 3 ...............................................................................................................
`
`10
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 3
`
`

`
`Contains nonbinding recommendations
`
`Guidance for Industry'
`
`ANDAs: PharmaceuticalSolid Polymorphism
`Chemistry, Manufacturing, and Controls Information
`
`represents the Food and Drug Administration's (FDA's) current thinking on this topic.
`It
`This guidance,
`does not create or confer any rights for or on any person and does not operate to bind FDA or the public.
`You can use an alternativeapproach if the approach satisfies the requirements of the applicable statutes
`Ifyou want to discuss
`Ifyou
`an alternate approach, contact the appropriateFDA staff
`and regulations.
`cannot identify the appropriateFDA staff call
`the appropriatenumber
`listed on the title page of this
`document.
`
`INTRODUCTION2
`
`I.
`
`Chemistry, manufacturing, and controls (CMC) information must be submitted to support the
`approval of an abbreviated new drug application (ANDA).3 This guidance is intended to assist
`applicants with the submission of ANDAs when a drug substance4 CXiSts in polymorphic forms."
`Specifically, this guidance provides:
`
`(cid:127)
`
`FDA recommendations on assessing sameness6 when the drug substance
`polymorphic forms.
`
`exists in
`
`(cid:127) Decision trees that provide recommendations on monitoring and controlling polymorphs
`in drug substances and/or drug products.
`
`including this guidance, do not establish legally enforceable
`FDA's guidance documents,
`responsibilities.
`Instead, guidances describe the Agency's current thinking on a topic and should
`be viewed only as recommendations, unless specific regulatory or statutory requirements are
`
`i This guidance has been prepared by the Office of Generic Drugs (OGD) in the Office of Pharmaceutical Science
`the Food and Drug Administration (FDA).
`(OPS), Center
`for Drug Evaluation and Research (CDER) at
`2 Although issues relating to polymorphic forms may be relevant to new drug applications (NDAs),
`this guidance
`only addresses polymorphic forms in the context of ANDA approvals.
`see also section 505(j)(4)(A) of the Federal Food, Drug, and Cosmetic Act (the Act).
`3 See 21 CFR 314.94 (a)(9);
`the purposes of this guidance the terms drug substance and active ingredient are used interchangeably.
`4 For
`6 The terms polymorphic forms and polymorphs are synonymous and are used interchangeably in this guidance.
`to Section IV for more information.
`6 Refer
`intended to help industry with the most common types of polymorphs. A drug substance may
`7 This guidance is
`exist in many polymorphic forms, but some forms may be rare and not likely to form.
`For example, in one approved
`in reality only a subset of
`drug product, the drug substance can exist
`twenty polymorphic forms, but
`in at
`least
`polymorphic forms has the potential
`the process conditions used to manufacture the drug substance
`to develop under
`Therefore, we recommend that you consider only those polymorphs that are likely to form during
`and drug product.
`manufacture of the drug substance, manufacture of the drug product, or while the drug substance or drug product
`is
`in storage.
`
`1
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 4
`
`

`
`Contains nonbinding recommendations
`
`cited. The use of the word should in Agency guidances means that something is suggested or
`recommended, but not required.
`
`II.
`
`DEFINITION OF TERMS: POLYMORPHICFORMS AND POLYMORPHISM
`
`We recommend that ANDA applicants investigate whether the drug substance
`in question can
`in polymorphic forms. Polymorphic forms in the context of this guidance refer to
`exist
`crystalline and amorphous forms as well as solvate and hydrate forms, which are described
`below.
`
`(cid:127) Crystalline forms have different arrangementsand/or conformations of the molecules in
`the crystal
`lattice.
`
`(cid:127)
`
`(cid:127)
`
`Amorphous forms consist of disordered arrangementsof molecules that do not possess a
`distinguishable crystal
`lattice.
`
`Solvates are crystal forms containing either stoichiometric or nonstoichiometric amounts
`If the incorporated solvent is water, the solvate is commonly known as a
`of a solvent.
`hydrate.
`
`When a drug substance
`
`exists in polymorphic forms,
`
`it
`
`is said to exhibit polymorphism.
`
`III.
`
`GENERAL PRINCIPLES OF PHARMACEUTICALSOLID POLYMORPHISM
`
`A.
`
`Importance of Pharmaceutical Solid Polymorphism
`
`can have different chemical and physical properties,
`Polymorphic forms of a drug substance
`including melting point, chemical reactivity, apparent solubility,'° dissolution rate, optical and
`mechanical properties, vapor pressure,
`and density. These properties can have a direct effect on
`the ability to process and/or manufacture the drug substance
`and the drug product, as well as on
`drug product stability, dissolution, and bioavailability. Thus, polymorphism can affect the
`quality, safety, and efficacy of the drug product.
`
`B.
`
`Characterization of Polymorphs
`
`There are a number of methods that can be used to characterize polymorphs of a drug
`substance." Demonstration of a nonequivalent structure by single crystalX-ray diffraction is
`
`industry, Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances
`* Guidance for
`and New Drug Products: Chemical Substances,
`International Conference
`on Harmonisation (ICH), December 2000.
`SR Byrn, RR Pfeiffer, and JG Stowell. Solid-State Chemistry ofDrugs.
`2nd Edition, SSCI, Inc., West Lafayette,
`Indiana, 1999.
`10 Apparent solubility refers to the concentration of material at apparent equilibrium (supersaturation). Apparent
`solubility is distinct
`from true thermodynamic solubility, which is reached at
`infinite equilibrium time.
`" H Brittain.
`the characterization of polymorphs and solvates."
`"Methods for
`In HG Brittain (ed.) Polymorphism in
`Pharmaceutical Solids. Marcel Dekker, Inc., New York, 1999, pp. 227-278.
`
`2
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 5
`
`

`
`Contains nonbinding recommendations
`
`currently regarded as the definitive evidence of polymorphism. X-ray powder diffraction can
`also be used to provide unequivocal proof of polymorphism. Other methods, including
`microscopy, thermal analysis (e.g., differential scanning calorimetry, thermal gravimetric
`infrared [IR], Raman, solid-state
`analysis, and hot-stage microscopy), and spectroscopy (e.g.,
`[ssNMR]) are helpful to further characterize polymorphic forms.
`nuclear magnetic resonance
`
`C.
`
`Influence of Polymorphism On Drug Substance And Drug Product
`
`1.
`
`Influence on Solubility, Dissolution, and Bioavailability (BA) and
`Bioequivalence (BE)
`
`The solid-state properties of a drug substance
`can have a significant influence on the apparent
`Since polymorphic forms differ in their internal solid-state
`solubility of the drug substance.
`structure, a drug substance
`that exists in various polymorphic forms can have different aqueous
`solubilities and dissolution rates.12 When there are differences in the apparent solubilities of the
`various polymorphic forms, we recommend that you focus on the potential effect such
`differences can have on drug product bioavailability (BA) and bioequivalence (BE).13
`
`Whether drug product BA/BE can be affected by the differences in apparent solubilities of the
`various polymorphic forms depends on the various physiological
`factors that govern the rate and
`extent of drug absorption including gastrointestinal motility, drug dissolution, and intestinal
`the Biopharmaceutics Classification System (BCS)14, 15 provides a
`permeability.
`In this context,
`useful scientific framework for regulatory decisions regarding drug substance polymorphism.
`
`For a drug whose absorption is only limited by its dissolution, large differences in the apparent
`solubilities of the various polymorphic forms are likely to affect BA/BE. On the other hand, for
`a drug whose absorption is only limited by its intestinal permeability, differences in the apparent
`solubilities of the various polymorphic forms are less likely to affect BA/BE. Furthermore, when
`the apparent solubilities of the polymorphic forms are sufficiently high and drug dissolution is
`rapid in relation to gastric emptying, differences in the solubilities of the polymorphic forms are
`unlikely to affect BA/BE.
`
`"Effect of polymorphism and solid-state solvation on solubility and dissolution rate."
`12 HG Brittain and DJW Grant.
`In HG Brittain (ed.) Polymorphism in Pharmaceutical Solids. Marcel Dekker,
`Inc., New York, 1999,
`pp. 279-330.
`" Bioavailability (BA) is defined in 21 CFR 320.l(a)
`as "the rate and extent to which the active ingredient or active
`moiety is absorbed from a drug product and becomes available at the site of action." Bioequivalence (BE) is
`as "the absence of a significant difference
`defined in 21 CFR 320.l(e)
`in the rate and extent to which the active
`ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the
`site of drug action when administered at the same molar dose under similar conditions in an appropriately designed
`study."
`"A theoretical basis for a biopharmaceutic drug
`14 GL Amidon, H Lennernas, VP Shah, and JR Crison.
`the correlation of in vitro drug product dissolution and in vivobioavailability," Pharm. Res. 12:413-
`classification:
`420, 1995.
`" LX Yu, GL Amidon, JE Polli, H Zhao, M Mehta, DP Conner, VP Shah, LJ Lesko, M-L Chen, VHL Lee, and AS
`"Biopharmaceutics Classification System: The scientific basis for biowaiver extension." Pharm. Res.
`Hussain.
`19:921-925, 2002.
`
`3
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 6
`
`

`
`Contains nonbinding recommendations
`
`Upon demonstration of in-vivo bioequivalence between the generic drug productl6 and the
`reference listed drug (RLD)," in-vitro dissolution testing is then used to assess
`the lot-to-lot
`quality of the generic drug product. Drug product dissolution testing frequently provides a
`suitable means to identify and control the quality of the product from both the bioavailability and
`physical (stability) perspectives. In particular, inadvertent changes to the polymorphic form that
`may affect drug product BA/BE can often be detected by drug product dissolution testing.
`
`2.
`
`Influence on Manufacturing of the Drug Product
`
`Drug substance polymorphic forms can also exhibit different physical and mechanical properties,
`flowability, and compactibility, which in turn
`including hygroscopicity, particle shape, density,
`may affect processing of the drug substance and/or manufacturing of the drug product. Since an
`ANDA applicant should demonstratethat the generic drug product can be manufactured reliably
`using a validated process, we recommend that you pay close attention to polymorphism as it
`relates to pharmaceutical processing.
`
`The effect of polymorphism on pharmaceutical processing also depends on the formulation and
`the manufacturing process." For a drug product manufactured by direct compression, the solid-
`state properties of the active ingredient will
`likely be critical
`to the manufacture of the drug
`product, particularly when it constitutes the bulk of the tablet mass. On the other hand,
`for a
`drug product manufactured by wet granulation, the solid-state properties of the active ingredient
`are often masked by the resultant granulation, and the solid-state properties of the active
`ingredient are less likely to affect the manufacture of the drug product.
`In the context of the
`effect of polymorphism on pharmaceutical processing, what is most
`relevant is the ability to
`consistently manufacture a drug product that conforms to applicable in-process controls and
`release specifications.
`
`Polymorphic forms of the drug substance
`can undergo phase conversion when exposed to a range
`such as drying, milling, micronization, wet granulation, spray-
`of manufacturing processes,
`drying, and compaction. Exposure to environmental conditions such as humidity and
`temperature can also induce polymorph conversion. The extent of conversion generally depends
`on the relative stability of the polymorphs, kinetic barriers to phase conversion, and applied
`stress.20 Nonetheless, phase conversion generally is not of serious concern, provided that the
`conversion occurs consistently, as a part of a validated manufacturing process where critical
`manufacturing process variables are well understood and controlled, and when drug product
`BA/BE has been demonstrated.
`
`refers to a new drug product for which approval
`
`is sought
`
`in an ANDA submitted
`
`16 The term generic drug product
`under section 505(j) of the Act.
`listed drug means the listed drug identified by FDA as the drug
`17 See 21 CFR 314.3 (b) (providing that reference
`product upon which an applicant relies in seeking approval of its abbreviated application).
`* Section 505(j)(4)(A) provides
`that FDA must approve an ANDA if, among other
`things, the methods used in, or
`and packing of the drug are adequate to assure and
`the facilities and controls used for,
`the manufacture, processing,
`preserve its identity, strength, quality, and purity.
`" DA Wadke, ATM Serajuddin, and H Jacobson.
`"Preformulation testing."
`In HA Lieberman, L Lachman, and JB
`(eds.) Pharmaceutical Dosage Forms: Tablets (Vol. 1). Marcel Dekker, Inc., New York, 1989,
`Schwartz
`pp. 1-73.
`20 SR Vippagunta, HG Brittain, DJW Grant.
`
`"Crystalline solids," Adv. Drug Del. Rev. 48:3-26, 2001.
`
`4
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 7
`
`

`
`Contains nonbinding recommendations
`
`3.
`
`Influence on Stability
`
`Polymorphs can have different physical and chemical (reactivity) properties. The most
`thermodynamically stable polymorphic form of a drug substance
`is often chosen during
`development based on the minimal potential for conversion to another polymorphic form and on
`its greater chemical stability. However, a metastable form can be chosen for various reasons,
`including bioavailability enhancement. Since an ANDA applicant must demonstratethat the
`generic drug product exhibits adequatestability,21 we recommend that you focus on the potential
`effect that a polymorphic form can have on drug product stability. Nonetheless, because drug
`product stability is affected by a multitude of other factors,
`including formulation, manufacturing
`process, and packaging, it
`is the stability of the drug product and not stability of the drug
`substance polymorphic form that should be the most
`relevant measure of drug quality.
`
`IV.
`
`POLYMORPHISMAND SAMENESSIN ANDAs
`
`Section 505(j)(2) of the Act specifies that an ANDA must contain, among other things,
`information to show that the active ingredient in the generic drug product is the "same as"
`that of
`the RLD. Under section 505(j)(4) of the Act, FDA must approve an ANDA unless the agency
`finds, among other things, that the ANDA contains insufficient
`information to show that the
`active ingredient is the same as that in the RLD. FDA regulations implementing section 505(j)
`of the Act provide that an ANDA is suitable for consideration and approval if the generic drug
`product is the "same as"
`the RLD. Specifically, 21 CFR 314.92(a)(l) provides that the term
`"same as" means, among other things, "identical
`in active ingredient(s)." The drug substance
`in
`in the RLD if it meets
`a generic drug product is considered to be the same as the drug substance
`for identity.22
`the same standards
`
`When a United States Pharmacopeia (USP) monograph exists for a particular drug substance,
`for identity generally refer to the definition (e.g. chemical name, empirical formula,
`standards
`the beginning of the monograph. However, FDA may
`molecular structure, description) at
`that are material to the sameness of a drug substance.23
`prescribe additional standards
`
`Polymorphic forms of a drug substance differ in internal solid-state structure, but not in chemical
`structure. In the context of sameness of active ingredient(s) in the preamble to the 1992 final
`rule, FDA specifically rejected a proposal that would have required an ANDA applicant to show
`that the active ingredient in its generic drug product and the active ingredient in the RLD
`"exhibit the same physical and chemical characteristics, that no additional residues or impurities
`can result from the different manufacture or synthesis process and that the stereochemistry
`characteristics and solid state forms of the drug have not been altered."24 Therefore, differences
`in drug substance polymorphic forms do not render drug substances different active ingredients
`for the purposes of ANDA approvals within the meaning of the Act and FDA regulations.
`
`21 See footnote
`18.
`22 See preamble to the 1992 final rule (57 FR 17958; April 28, 1992).
`23 See footnote
`22.
`24 See footnote
`22.
`
`5
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 8
`
`

`
`Contains nonbinding recommendations
`
`for identity, each ANDA applicant is required to
`In addition to meeting the standards
`demonstrate that, among other things, the drug product exhibits sufficient stability and is
`bioequivalent to the RLD.25 While the polymorphic form can affect drug product stability and
`bioequivalence, these performance characteristics are also dependent on the formulation,
`the
`manufacturing process, and other physicochemical properties (e.g., particle size, moisture) of
`both the drug substance
`and formulation excipients. Using a drug substance polymorphic form
`that is different from that of the RLD may not preclude an ANDA applicant from formulating a
`generic drug product that exhibits bioequivalence and stability, and the drug substance
`in the
`generic drug product need not have the same polymorphic form as the drug substance
`in the
`RLD.
`
`Over the years, FDA has approved a number of ANDAs in which the drug substance
`in the
`generic drug product had a different polymorphic form from the drug substance
`in the respective
`RLD (e.g., warfarin sodium, famotidine, and ranitidine). FDA also has approved some ANDAs
`in which the drug substance
`in the generic drug product differed in solvate or hydrate forms from
`the drug substance
`in the corresponding RLD (e.g., terazosin hydrochloride, ampicillin, and
`cefadroxil).
`
`V.
`
`CONSIDERATIONS FOR POLYMORPHISMIN ANDAs
`
`to 3 provide ANDA applicants with a suggested
`The decision trees shown in Attachments 1
`for evaluating the importance of and approachesto setting specifications for
`process
`polymorphic forms in solid oral drug products and oral suspensions.
`Although the conceptual
`framework adopted by these decision trees is based primarily on the potential for polymorphic
`forms to affect drug product BA/BE, we recommend that you still consider the influence
`polymorphic forms may have on the ability to manufacture the drug product and on the stability
`of the drug product.
`
`The following sections describe each of the decision trees.
`
`Investigating the Importance of Setting Specifications for Polymorphs
`A.
`Decision Tree 1 provides recommendations on when specifications for polymorphic form(s)26
`for the drug substance and/or the drug product may be appropriate. Polymorphs are unlikely to
`have a significant effect on BA/BE when all forms have the same apparent solubilities or all
`forms are highly soluble.
`
`ANDA applicants are expected to have adequateknowledge about drug substance polymorphs.
`Information on polymorphism can come from the scientific literature, patents, compendia, other
`references,or in some cases, polymorph screening.
`
`B.
`
`Setting Specifications for Polymorphs in Drug Substances
`
`25 See 505(j)(4) of the Act and 21 CFR 314.127.
`26 See footnote 7.
`
`6
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 9
`
`

`
`Contains nonbinding recommendations
`
`Decision Tree 2 provides an approach for setting specifications for polymorphs in the drug
`If relevant
`least one form is known to have low solubility based on the BCS.
`substance when at
`and adequate specifications for polymorphs are included in the USP, ANDA applicants may
`adopt these specifications for the drug substance polymorphic form. Otherwise, we recommend
`that a new specification for the drug substance polymorphic form be established.
`
`C.
`
`Investigating the Importance of Setting Specifications for Polymorphs in
`Drug Products
`
`Decision Tree 3 provides an approach when considering whether to set specifications for
`polymorphs in the drug product. Generally, specifications for polymorphs in drug products are
`if the most
`thermodynamically stable polymorphic form is used or if the same
`not necessary
`form is used in an approved product of the same dosage form. However, since manufacturing
`can affect the polymorphic form, we recommend that you use caution if a metastable
`processes
`form is used.
`
`Drug product performance testing (e.g., dissolution testing) can also generally provide adequate
`control of polymorph ratio changes
`that can influence drug product BA/BE for poorly soluble
`In such instances,
`setting specifications for polymorphs in the drug product would
`drugs.
`generally not be considered important for ensuring adequate product performance. Only in rare
`cases would we recommend setting specifications for polymorphic forms in drug products.
`
`7
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 10
`
`

`
`Contains nonbinding recommendations
`
`ATTACHMENT1-DECISIONTREE 1
`
`Decision Tree 1
`
`Investigating whether to set specifications for polymorphs for solid oral
`and suspensiondosage form products.
`
`NO
`
`Polymorphic form specifications in both the drug
`substance and the drug product
`are unnecessary
`

`
`YES
`
`START
`
`Are there known
`polymorphs
`with different
`apparent
`solubilities?
`
`YES
`
`Are all polymorphs
`highly soluble as
`defined by BCS
`criteria?
`
`NO
`
`Decision Tree 2
`
`*We recommend that you consider only those polymorphs that are likely to form during manufacture of the drug
`substance, manufacture of the drug product, or while the drug substance or drug product
`is in storage.
`See footnote
`7 in this guidance document.
`
`8
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 11
`
`

`
`Contains nonbinding recommendations
`
`ATTACHMENT2 -- DECISION TREE 2
`
`Decision Tree 2
`
`Setting specifications for polymorphs in drug substances
`dosage form products.
`suspension
`
`for solid oral and
`
`START
`
`Is there a
`polymorph
`specification in the
`USP (e.g., melting
`point)?
`
`NO
`
`YES
`
`Is the polymorph
`specification in the
`USP relevant and
`adequate?
`
`NO
`
`Set a new specification for the drug substance
`polymorphic form.
`
`YES
`
`the same specification for the
`Set
`drug substance polymorphic form as
`in the USP.
`
`,,
`Decision Tree 3
`
`B
`
`9
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 12
`
`

`
`Contains nonbinding recommendations
`
`ATTACHMENT3 - DECISION TREE 3
`
`Decision Tree 3
`
`Investigating whether to set specifications for polymorphs in drug
`dosage form products.
`products for solid oral and suspension
`
`START
`
`a
`
`Is there sufficient
`concern that
`polymorph
`specification in the
`drug product be
`established?*
`
`YES
`
`Does drug product
`performance testing
`(e.g., dissolution
`testing) provide
`adequate controls if
`the polymorph ratio
`changes?
`
`NO
`
`NO
`
`YES
`

`
`b
`
`A polymorph specification in
`is unnecessary.
`the drug product
`
`a specification for drug
`Set
`product performance testing
`(e.g., dissolution testing) as
`surrogate for polymorph
`in the drug product.
`control
`
`a
`
`a polymorph specification in the drug product
`Set
`using other approaches, such as a solid-state characterization method.**
`
`*In general,
`there may not be a concern if the most thermodynamically
`stable polymorphic form
`is used or the same form is used in a previously approved product of the same dosage form.
`
`**Drug product performance testing (e.g., dissolution testing) can generally provide adequate
`control of polymorph ratio changes for poorly soluble drugs, which may influence drug product
`BA/BE. Only in rare cases would polymorphic form characterization in the drug product
`be
`recommended.
`
`10
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 13

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket